The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Oh yes - I got in at just under 15 and was not tempted to sell at 32 nor when it went down to 14 something. I've been confident all along in the science and the company. Looking forward to the next set of results because I think they'll bring in a lot more buyers. I envisage holding for at least another three years by which time I think we'll very significantly higher.
Realising some £13.1 million from a £400,000 investment isn't going to hurt the figures. Just wish I'd bought some Tracsis shares too when they became available to PIs.
Well their report looks pretty convincing to me. Do these carry any weight with the market? I'm sure our major investors such as Invesco and Woodford will know all this already and have come to their own conclusions, but maybe it will help move sentiment our way?
Well at least there's some good news in my portfolio today! Hopefully we'll be moving towards critical mass now - assuming the product is a good as we all hope the success stories will start to mount up and medical practitioners will turn towards it even more.
The last of the 20 patients for the orthopure meniscus trial has now had their operation. http://www.ipgroupplc.com/media/portfolio-news/2016/2016-01-18a. Not dramatic enough news to stem falls in the current market conditions but another stage passed which helps manage our expectations: "Peter Hamer, Commercial Director of Orthopaedics at Tissue Regenix said "We are delighted to announce the completion of enrolment for the OrthoPure™ XM clinical trial. The strict selection criteria meant that there was only a small pool of patients which could be considered to validate the safety and success of the treatment. It is a testament to the hard work of both our research and development teams, and the clinical trial centres, that we have remained on course for CE mark submission by Q4 and hope to secure approval of the first of our dCELL® orthopaedic product by the end of the year."
Those of us who've been hanging around here for a while agree obviously. Last year's results included only the first few months of dermapure being commercially available and the impatient market seemed to look and think - not enough going on there yet. There's progress being made across all our exciting products but you may find there's not much activity here until the next set of figures come out and give the market an idea about how well dermapure is being taken up - that should be early May.
Nice little boost for us here (from Proactive Investors): Tissue Regenix (LON:TRX) has made it onto Jefferies’ list of top drug industry buys for 2016, with the broker saying it could be a takeover target. The firm, which has created a porcine tendon for use in anterior cruciate ligament (ACL) and meniscus surgery, has a number of catalysts for shares in the new year, the broker said. Tissue has also developed a skin graft product, again from pigs, as well as heart valves. The broker said after raising £19mln in February to help develop its meniscus and ligament product - OrthaPure – that it expects the product to be launched by the end of next year. This has led to a rise in its forecasts for the year, with sales expected to be around £18mln rather than £13mln, while earnings [EBITDA] losses are likely to be reduced to £17mln from previous estimates of £22mln, with the firm swinging to a profit by 2017. Meanwhile, “the company sees promising data coming through from its cardiac product (heart valve), which is another large attractive market, in our view,” Jefferies said. It also notes, that with larger firms always on the look-out for new products, “it is not unlikely that Tissue Regenix could become a takeover target.” “The large medical device companies are grappling with how to move beyond traditional solutions, and TRX is positioned to deliver a neat product that is affordable to bring to market and cost-effective for the payer,” Jefferies said.
Ok big fall this morning on very little trading. I can't believe this is some terrible news seeping out - just suppose its market makers trying something in the absence of much news or activity. Whatever - this looks like a good time to top up or enter the game if you've been studying this one. I've not got spare cash right now but this is the level I did originally buy at and would do so again if I could.
Appreciate you are not being entirely serious, but as the gaffer says in that video, the fact is that we are all going to live for a lot longer than our bodies are ready for, so there will be an ever increasing number of body parts that need replacing or patching up.
A very nice, upbeat little video from the Daily Telegraph here featuring key Trx and academic staff bigging up our prospects http://www.telegraph.co.uk/finance/businessclub/business-club-video/technology-sector-videos/11971985/tissue-regenix-group.html
That's quite an exciting report. I'm a bit mystified as to why they put estimated revenue for the year to 01.16 as just 0.4m. The interims have us doing 0.3m up to the end of July. Am I missing something or are they?
Well, that appears to have been the scenario. Progress, but not especially exciting figures, though seemingly more or less what the market expected, and we all just have to wait a bit longer. See you all in six months.
Big day coming up for us on Monday. Have to hope that the fall over last two months (well 18 months but the last two in particular) mean that any poor to average figures will have been priced in somewhat. I keep telling myself this is still early days for a biomedical company - but it would be good to get some positive progress on sales of dermapure. I'm quietly confident.
So what's with all these sells this month? Any Ideas? They can't all be misreported buys.
Seeing they've arranged a capital markets day to coincide with the interim results announcement in October, would it be too much to infer that they might have good news to share?
Bizarre. Can only assume it will creep back up during the day as people come to their senses.
Ok, so now we do have the results for 2014. We now look a financially sound company in search of something to do.
Hmm, ignore that last post - just noticed the article put up on Friday by yahoo refers to 2011 - presumably some kind of automated glitch saw it being reposted.